case_images: PMC7591674_01
case_images: Clinical presentation of the patient before the treatment with Apremilast (A). Resolution of psoriasis after the treatment with Apremilast (B).
case_images: fonc-10-579445-g001.jpg
case_images: PMC7591674_01_fonc-10-579445-g001.jpg
case_images: F1
case_images: After the 10th cycle, he developed psoriasis with itchy, multiple, well-marked, and raised, red plaque spread on >30% of the body surface [12.3 Psoriasis Area and Severity Index (PASI) score] (Figure 1A). Furthermore, Pembrolizumab was interrupted for 4 weeks until the improvement of skin manifestations and disappearance of itching (Figure 1B).
case_images: PET scan liver images before starting treatment with Pembrolizumab showing a pathologic standardized uptake value (SUV) (A). After 18 cycles of treatment, PET scan showing iRECIST complete response (B).
case_images: fonc-10-579445-g002.jpg
case_images: PMC7591674_01_fonc-10-579445-g002.jpg
case_images: F2
case_images: A positron emission tomography (PET) scan revealed pathological uptake of 18F-fluorodeoxyglucose (18-FDG) in the liver (Figure 2A). Moreover, PET and computed tomography (CT) scans showed no evidence of previously described melanoma lesions (complete response as per iRECIST) (Figure 2B).
case_images: Case report timeline.
case_images: fonc-10-579445-g003.jpg
case_images: PMC7591674_01_fonc-10-579445-g003.jpg
case_images: F3
case_images: A chronological summary of the case report is shown in Figure 3.